← SynDRA
PIMASERTIB
SynDRA canonical compound SYN0033276 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAP2K2 |
|---|
| Mechanism of action | MEK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MEK inhibitor
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Cross-references
Synonyms
- AS-703026
- Msc-1936369
- AS703026
- EMD-1036239
- G-02443714
- MSC-1936369A
- MSC-1936369B
- MSC1936369A
- Msc1936369a; as703026; emd 1036239
- AS 703026
- 6ON9RK82AL
- MSC-1936369
- pimasertibum
- RefChem:863289
- MSC1936369
- Pimasertib (AS-703026)
- MSC1936369B
- MFCD16660676
- Pimasertib [INN]
- Pimasertib [USAN:INN]
- UNII-6ON9RK82AL
- C15H15FIN3O3
- AS703026Pimasertib
- Pimasertib (USAN/INN)
- PIMASERTIB [USAN]
- EPZ011989 Hydrochloride
- PIMASERTIB [WHO-DD]
- MLS006010177
- GTPL7872
- orb1301047
- orb1738240
- SCHEMBL2720659
- SCHEMBL29358435
- CHEBI:94793
- EX-A403
- GLXC-90182
- BDBM50014412
- EBC-11474
- NSC755763
Look up PIMASERTIB in the interactive SynDRA portal →